Patents by Inventor Benjamin Strobel

Benjamin Strobel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VIRAL VECTORS AND NUCLEIC ACIDS FOR REGULATED GENE THERAPY
    Publication number: 20240076689
    Abstract: This invention generally relates to the field of somatic gene therapy. The invention provides a nucleic acid construct comprising a transgene encoding a therapeutic protein, a tetracycline-responsive aptazyme sequence, and inverted terminal repeats (ITRs). The nucleic acid construct can be transferred to a subject in need thereof in the form of a viral vector, in particular an adeno-associated virus (AAV) vector. The Tet-responsive aptazyme sequence allows for a tightly controlled expression of the transgene in the subject, thereby avoiding toxic side effects. The nucleic acid construct and the viral vectors comprising same are particularly useful in the treatment of proliferative diseases like cancer.
    Type: Application
    Filed: May 17, 2021
    Publication date: March 7, 2024
    Inventors: John Park, Philipp MÜLLER, Sebastian KREUZ, Benjamin STROBEL, Matthias DÜCHS, Matthias KLUGMANN, Stefan MICHELFELDER, Dragica BLAZEVIC, Romona KRATZER
  • VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF
    Publication number: 20240011033
    Abstract: Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model.
    Type: Application
    Filed: November 4, 2021
    Publication date: January 11, 2024
    Inventors: Sebastian Kreuz, Ludger Ickenstein, Marc Kaestle, Stephan Klee, Holger Klein, Thorsten Lamla, Benjamin Strobel
  • VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF
    Publication number: 20230416738
    Abstract: Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF #1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF #1-induced lung fibrosis model.
    Type: Application
    Filed: November 4, 2020
    Publication date: December 28, 2023
    Inventors: Sebastian Kreuz, Holger Klein, Benjamin Strobel, Stephan Klee, Thorsten Lamla, Marc Kaestle, Ludger Ickenstein
  • VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF
    Publication number: 20230407303
    Abstract: Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model.
    Type: Application
    Filed: November 4, 2021
    Publication date: December 21, 2023
    Inventors: Sebastian Kreuz, Holger Klein, Benjamin Strobel, Stephan Klee, Thorsten Lamla, Marc Kaestle, Ludger Ickenstein
  • USE OF BIOMARKERS IN THE TREATMENT OF FIBROTIC CONDITIONS
    Publication number: 20230135671
    Abstract: Genes selected from CEACAM6, CEACAM8, CTSG, DEFA4, LTF, MMP8, OLFM4, OLR1, SHISA4, ABCA13, EMID1, LMOD1, MPO, and PRTN3 can be used as biomarkers in methods for the treatment of progressive fibrosing interstitial lung diseases.
    Type: Application
    Filed: March 30, 2021
    Publication date: May 4, 2023
    Inventors: Benjamin STROBEL, Patrick BAUM, Claudia DIEFENBACH
  • VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF PF-ILD AND IPF
    Publication number: 20220213503
    Abstract: Viral vector comprising: a capsid and a packaged nucleic acid, wherein the nucleic acid either augments the miRNA downregulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model, or wherein the nucleic acid inhibits the miRNA up-regulated in a Bleomycin-induced lung fibrosis model or in an AAV-TGF?1-induced lung fibrosis model.
    Type: Application
    Filed: April 30, 2020
    Publication date: July 7, 2022
    Inventors: Sebastian Kreuz, Holger Klein, Benjamin Strobel, Stephan Klee, Thorsten Lamla, Marc Kaestle